Efficacy and safety of lorundrostat in patients with uncontrolled or resistant hypertension: A systematic review and meta-analysis with trial sequential analysis
Vascular Pharmacology · 2025-12 · 161 · 107550
DOI: 10.1016/j.vph.2025.107550 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Vascular Pharmacology, 2025-12. Verfasst von Laila Shalabi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Gharyan University, Gharyan, Libya. Electronic address: Laila.shalabi@gu.edu.ly. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Uncontrolled hypertension (HTN) remains a challenge despite multiple anti-hypertensive medications. This study systematically evaluates the efficacy and safety of Lorundrostat, a novel aldosterone synthase inhibitor, in patients with uncontrolled hypertension. METHODS: A comprehensive search of major electronic databases was conducted until Jul 14, 2025, to identify randomized controlled trials (RCTs) comparing Lorundrostat with placebo. The primary outcomes included changes in office systolic and diastolic blood pressure (BP). A random-effects model was used to pool the data, presented as risk ratios (RR) or mean differences (MD) with 95 % confidence intervals (CIs). RESULTS: The pooled analysis of three RCTs comprising 1562 patients demonstrated that lorundrostat yielded statistically significant reductions in both office systolic BP (MD = -8.26 mmHg; 95 % CI: -10.87 to -5.64; p < 0.0001) and diastolic BP (MD = -3.53 mmHg; 95 % CI: -5.62 to -1.43; p = 0.001). However, Lorundrostat was associated with increased risks of hyperkalemia (RR = 7.93; 95 % CI: 1.55 to 40.64; p = 0.0131), hyponatremia (RR = 1.96; 95 % CI: 1.15 to 3.35; p = 0.0133), hypotension (RR = 3.06; 95 % CI: 1.15 to 8.11; p = 0.0250), and any adverse events (RR = 1.47; 95 % CI: 1.29 to 1.67; p < 0.0001). CONCLUSION: Lorundrostat effectively controls blood pressure in patients with uncontrolled hypertension; however, it also increases the incidence of adverse events, and further large-scale trials are needed to confirm long-term efficacy and safety. PROSPERO ID: CRD420251107424.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Gharyan University, Gharyan, Libya. Electronic address: Laila.shalabi@gu.edu.ly.
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
- Faculty of Medicine, Near East University, Nicosia, Cyprus.
- Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
- Faculty of Medicine, Tanta University, Tanta, Egypt.
Zitieren
APA
Shalabi, L., Tawfik, A. M., Al Zoubi, B. M., Al Othman, A., Zreigh, S., & Abuelazm, M. (2025). Efficacy and safety of lorundrostat in patients with uncontrolled or resistant hypertension: A systematic review and meta-analysis with trial sequential analysis. Vascular Pharmacology, 161, 107550. https://doi.org/10.1016/j.vph.2025.107550
Vancouver
Shalabi L, Tawfik AM, Al Zoubi BM, Al Othman A, Zreigh S, Abuelazm M. Efficacy and safety of lorundrostat in patients with uncontrolled or resistant hypertension: A systematic review and meta-analysis with trial sequential analysis. Vascular Pharmacology. 2025;161:107550. doi:10.1016/j.vph.2025.107550
BibTeX
@article{Shalabi2025,
author = {Shalabi, Laila and Tawfik, Abdelrahman M and Al Zoubi, Bashar M and Al Othman, Ahmad and Zreigh, Sofian and Abuelazm, Mohamed},
title = {Efficacy and safety of lorundrostat in patients with uncontrolled or resistant hypertension: A systematic review and meta-analysis with trial sequential analysis},
journal = {Vascular Pharmacology},
year = {2025},
volume = {161},
pages = {107550},
doi = {10.1016/j.vph.2025.107550}
}
EUVIMED